SNAP

Snap stock declined 4.81% on October 16, 2026, outpacing the broader market's 1.09% loss. Despite recent gains of 13.98% prior to this trading day, the stock faces upcoming earnings on November 4, 2026.

Analysts expect strong year-over-year growth with EPS of $0.16 (up 166.67%) and revenue of $1.72 billion (up 14.33%). Snap trades at a Forward P/E of 10.98, below its industry average of 21.23, and holds a Zacks Rank #3 (Hold) rating.

Snap (SNAP) declined 6.01% in trading, underperforming the S&P 500's 1.11% loss. The company is set to report earnings on November 4, 2026, with analysts expecting $0.16 EPS (166.67% YoY growth) and $1.72B revenue (14.33% growth).

For the full year, consensus estimates project $0.59 EPS and $6.78B revenue. SNAP trades at a Forward P/E of 11.06, below the industry average of 20.8, and holds a Zacks Rank #3 (Hold) rating.

Hims & Hers Health (NYSE: HIMS) faces a securities class action lawsuit following an FTC complaint alleging the company deceptively shared consumers' health data with third-party advertising platforms like Meta and Snap, and violated billing regulations by charging for prescriptions before medical consultations. The stock plunged 14.7% on July 29, 2026, erasing over $970 million in market value.